KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial

Summary

Participation Requirements

Description

Neovascular glaucoma (NVG) has a high blinding rate and poor prognosis. Anti-glaucoma surgery is the main way of saving visual function and relieving pain, but the proliferation of iris neovascularization (NVI) makes it difficult to treat NVG. Normally, the patients need intravitreal injection of an...

Neovascular glaucoma (NVG) has a high blinding rate and poor prognosis. Anti-glaucoma surgery is the main way of saving visual function and relieving pain, but the proliferation of iris neovascularization (NVI) makes it difficult to treat NVG. Normally, the patients need intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) agents prior to glaucoma surgery to control the NVI proliferation. KDR2-2, a novel small-molecule tyrosine kinase inhibitor targeting VEGF receptor 2 (VEGFR2), has demonstrated anti-neovascular effect without obvious side-effects or complications in animal studies and Phase I clinical trial (NCT04620109). In this study, 20 patients with NVG will be included to evaluate the effect of KDR2-2 suspension eyedrop on NVI in NVG eyes. The included subjects would be randomized to receive either 0.96 or 4.8 mg/day/eye, in a QID fashion, ×7 days (those without complications can continue to 28 days). This study aims to and propose a novel, non-invasive and more compliant method for the treatment of NVG.

Tracking Information